July 31 Preclinical Quick Takes: Sangamo reveals new gene editors; plus a CRISPR prediction model and vaccine boosters for ischemia

Sangamo unveils next-gen ZFN editors
In a Nature Biotechnology study, Sangamo Therapeutics Inc. (NASDAQ:SGMO) reported a next generation zinc finger nuclease (ZFN) gene editing technology with amino acid substitutions

Read the full 288 word article

User Sign In